IP6K2 is a client for HSP90 and a target for cancer therapeutics development.
Shames
David S
DS
The Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, and Departments of Pharmacology and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Minna
John D
JD
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis; D015195:Drug Design; D018841:HSP90 Heat-Shock Proteins / Q000378:metabolism*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D017856:Phosphotransferases (Phosphate Group Acceptor) / Q000378:metabolism*
D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; D017856:Phosphotransferases (Phosphate Group Acceptor); C099438:inositol hexakisphosphate kinase